drugset / Trial / NCT05221138

Food Effect on Pharmacokinetic Profiles of VV116 Administered Orally to Chinese Healthy Volunteers

NCT05221138

Phase 1 Completed 12 enrolled Vigonvita Life Sciences
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a single-center, randomized, open-label, three-period crossover design, the objective is to evaluate the pharmacokinetics and safety of VV116 tablets, which are orally administered to Chinese healthy volunteers after fasting, standard diet or high-fat diet.

Timeline

Start
2021-12-30
Primary completion
2022-01-19
Completion
2022-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject REMIDEVIR Small molecule 400 mg Oral

Indications

No indication recorded.